179 related articles for article (PubMed ID: 38275742)
1. Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response.
Ortiz MA; Diaz-Torné C; De Agustin JJ; Estrada P; Reina D; Hernandez MV; Sang H; Zamora C; Cantó E; Corominas H; Vidal S
Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38275742
[TBL] [Abstract][Full Text] [Related]
2. B cells from Patients with Rheumatoid Arthritis Show Conserved CD39-Mediated Regulatory Function and increased CD39 Expression After Positive Response to Therapy.
Zacca ER; Amezcua Vesely MC; Ferrero PV; Acosta CDV; Ponce NE; Bossio SN; Mussano E; Onetti L; Cadile I; Acosta Rodríguez EV; Montes CL; Gruppi A
J Mol Biol; 2021 Jan; 433(1):166687. PubMed ID: 33098857
[TBL] [Abstract][Full Text] [Related]
3. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis.
Peres RS; Liew FY; Talbot J; Carregaro V; Oliveira RD; Almeida SL; França RF; Donate PB; Pinto LG; Ferreira FI; Costa DL; Demarque DP; Gouvea DR; Lopes NP; Queiroz RH; Silva JS; Figueiredo F; Alves-Filho JC; Cunha TM; Ferreira SH; Louzada-Junior P; Cunha FQ
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2509-14. PubMed ID: 25675517
[TBL] [Abstract][Full Text] [Related]
4. Identification of CD4
Fan W; Wang W; Wu J; Ma L; Guo J
Biomark Med; 2017 Feb; 11(2):107-116. PubMed ID: 28111965
[TBL] [Abstract][Full Text] [Related]
5. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
[TBL] [Abstract][Full Text] [Related]
6. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
[TBL] [Abstract][Full Text] [Related]
7. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
Pulte D; Furman RR; Broekman MJ; Drosopoulos JH; Ballard HS; Olson KE; Kizer JR; Marcus AJ
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):367-72. PubMed ID: 21816376
[TBL] [Abstract][Full Text] [Related]
8. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
9. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.
Thiolat A; Semerano L; Pers YM; Biton J; Lemeiter D; Portales P; Quentin J; Jorgensen C; Decker P; Boissier MC; Louis-Plence P; Bessis N
Arthritis Rheumatol; 2014 Feb; 66(2):273-83. PubMed ID: 24504799
[TBL] [Abstract][Full Text] [Related]
11. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
13. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury.
Bönner F; Borg N; Burghoff S; Schrader J
PLoS One; 2012; 7(4):e34730. PubMed ID: 22514659
[TBL] [Abstract][Full Text] [Related]
14. CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice.
Alam MS; Kurtz CC; Rowlett RM; Reuter BK; Wiznerowicz E; Das S; Linden J; Crowe SE; Ernst PB
J Infect Dis; 2009 Feb; 199(4):494-504. PubMed ID: 19281303
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5'-nucleotidase (CD73) in pig aortic valves.
Kaniewska E; Sielicka A; Sarathchandra P; Pelikant-Małecka I; Olkowicz M; Słomińska EM; Chester AH; Yacoub MH; Smoleński RT
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):305-12. PubMed ID: 24940684
[TBL] [Abstract][Full Text] [Related]
16. CD39/CD73/A2a Adenosine Metabolic Pathway: Targets for Moxibustion in Treating DSS-Induced Ulcerative Colitis.
Zhu Y; Zhuang Z; Wu Q; Lin S; Zhao N; Zhang Q; Xie L; Yu S
Am J Chin Med; 2021; 49(3):661-676. PubMed ID: 33683190
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection.
Jenabian MA; Seddiki N; Yatim A; Carriere M; Hulin A; Younas M; Ghadimi E; Kök A; Routy JP; Tremblay A; Sévigny J; Lelievre JD; Levy Y
PLoS Pathog; 2013; 9(4):e1003319. PubMed ID: 23658513
[TBL] [Abstract][Full Text] [Related]
18. Elevated CD39+T-Regulatory Cells and Reduced Levels of Adenosine Indicate a Role for Tolerogenic Signals in the Progression from Moderate to Severe COVID-19.
Elsaghir A; El-Sabaa EMW; Zahran AM; Mandour SA; Salama EH; Aboulfotuh S; El-Morshedy RM; Tocci S; Mandour AM; Ali WE; Abdel-Wahid L; Sayed IM; El-Mokhtar MA
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139439
[TBL] [Abstract][Full Text] [Related]
19. Target tissue ectoenzyme CD39/CD73-expressing Foxp3+ regulatory T cells in patients with psoriasis.
Zhang HY; Yan KX; Huang Q; Ma Y; Fang X; Han L
Clin Exp Dermatol; 2015 Mar; 40(2):182-91. PubMed ID: 25284153
[TBL] [Abstract][Full Text] [Related]
20. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
